IL-11 is a strong candidate but not yet a universal bottleneck

IL-11 is a strong candidate but not yet a universal bottleneck

''结论'': IL-11 is unusual among inflammation-axis candidates because it has direct mouse healthspan/lifespan data (Nature 2024), but that does **not** make it a universal longevity bottleneck. The counterweight is pleiotropy: IL-11 is also implicated in regeneration programs and bone homeostasis, so systemic inhibition may carry repair/development trade-offs. Therefore, a mouse lifespan hit is sufficient to keep IL-11 on the short list, but insufficient to upgrade it above all other immune/inflammation candidates without human-relevant safety and necessity data.